Shanghai MicroPort MedBot Group Co. Ltd. announced that its core product, the Toumai® Laparoscopic Surgical Robot, has received over 200 commercial orders worldwide, covering nearly 50 countries and regions. The company has also achieved commercial installations of approximately 130 units. The Toumai system has been approved for commercial use in nearly 10 countries, including China, India, and Brazil, and has completed nearly 800 remote surgeries across more than 20 countries. The information disclosed is unaudited and based on preliminary internal data.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai MicroPort MedBot Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260212-12023736), on February 12, 2026, and is solely responsible for the information contained therein.